Calcium, vitamin D or recombinant parathyroid hormone for managing post-thyroidectomy hypoparathyroidism.

What It Covers

This systematic review looks at Vitamin D, K2, Magnesium and Zinc and Parathyroid Hormone (PTH 1-84).

Existing guidelines do not often distinguish between surgical and non-surgical hypoparathyroidism, and transient and long-term disease.The aim of this systematic review was to summarise evidence on the use of calcium, vitamin D and recombinant parathyroid hormone in the management of post-thyroidectomy hypoparathyroidism.

The objective of this systematic review was to assess the effects of calcium, vitamin D and recombinant parathyroid hormone in managing post-thyroidectomy hypoparathyroidism.

Why It Was Studied

Post-surgical hypoparathyroidism is a common complication after thyroid surgery.

The management of post-thyroidectomy hypoparathyroidism however has not been extensively evaluated.

How the Review Was Done

The researchers searched CENTRAL, MEDLINE, PubMed, Embase as well as ICTRP Search Portal and ClinicalTrials.gov.

The date of the last search for all databases was 17 December 2018 (except Embase, which was last searched on 21 December 2017).

No language restrictions were applied.

What Was Measured

The management of post-thyroidectomy hypoparathyroidism however has not been extensively evaluated.

The subject headings attached to it are Calcium, Dietary, Dietary Supplements, Hypoparathyroidism, Parathyroid Hormone, Thyroidectomy and Vitamin D.

What This Means in Plain Language

This is a systematic review of Vitamin D, K2, Magnesium and Zinc and Parathyroid Hormone (PTH 1-84).

Its findings take up roughly 5 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2019 (The Cochrane database of systematic reviews), a journal based in England.

More context: the Vitamin D, K2, Magnesium and Zinc compound page and the Parathyroid Hormone (PTH 1-84) compound page, all human trials.